OBJECTIVE: Extracorporeal membrane oxygenation (ECMO) offers temporary haemodynamic support for those with refractory cardiogenic shock after cardiac surgery. We review our 5-year experience regarding ECMO use on those who cannot be weaned from cardiopulmonary bypass after cardiac surgery. We analyse our cases, predict the prognostic factors of survival and compare the short-term and medium-term results. METHODS: From January 2002 to December 2006, 1764 patients underwent cardiac surgery with cardiopulmonary bypass in our division. Among these, 51 patients (2.9%) required venoarterial-mode ECMO for haemodynamic support because of refractory postcardiotomy cardiogenic shock. The indication of ECMO was refractory cardiogenic shock despite adequate filling volumes, large-dose inotropes and intra-aortic balloon pump support. The following cardiac surgical procedures were performed: coronary artery bypass grafting (CABG), n=27; valvular surgery, n=11; CABG plus valvular surgery, n=7; heart transplantation, n=4 and other procedures, n=2. RESULTS: Average age was 63.0+/-15.7 years. There were 36 male and 15 female patients. Average duration of ECMO was 7.5+/-6.7 days. Twenty-seven (53%) patients could be successfully weaned from ECMO. The 30-day and 3-month mortalities were 49% (25/51) and 65% (33/51). The in-hospital mortality was 67% (34/51 patients). Seventeen (33%) patients could be successfully discharged. Fifteen (29%) patients were still alive at 1-year outpatient department (OPD) follow-up. CONCLUSIONS: ECMO provides a good temporary cardiopulmonary support in patients with postcardiotomy shock. The preoperative risk factors of failure to withdraw ECMO are poor left-ventricular ejection fraction, systolic blood pressure <90 mmHg and refractory severe metabolic acidosis. The peri-ECMO predictors of mortality include low serum albumin level, low platelet count, low oxygen pressure of the venous tube of the ECMO and poor cardiac systolic function. Crown Copyright 2009. Published by Elsevier B.V. All rights reserved.
OBJECTIVE: Extracorporeal membrane oxygenation (ECMO) offers temporary haemodynamic support for those with refractory cardiogenic shock after cardiac surgery. We review our 5-year experience regarding ECMO use on those who cannot be weaned from cardiopulmonary bypass after cardiac surgery. We analyse our cases, predict the prognostic factors of survival and compare the short-term and medium-term results. METHODS: From January 2002 to December 2006, 1764 patients underwent cardiac surgery with cardiopulmonary bypass in our division. Among these, 51 patients (2.9%) required venoarterial-mode ECMO for haemodynamic support because of refractory postcardiotomy cardiogenic shock. The indication of ECMO was refractory cardiogenic shock despite adequate filling volumes, large-dose inotropes and intra-aortic balloon pump support. The following cardiac surgical procedures were performed: coronary artery bypass grafting (CABG), n=27; valvular surgery, n=11; CABG plus valvular surgery, n=7; heart transplantation, n=4 and other procedures, n=2. RESULTS: Average age was 63.0+/-15.7 years. There were 36 male and 15 female patients. Average duration of ECMO was 7.5+/-6.7 days. Twenty-seven (53%) patients could be successfully weaned from ECMO. The 30-day and 3-month mortalities were 49% (25/51) and 65% (33/51). The in-hospital mortality was 67% (34/51 patients). Seventeen (33%) patients could be successfully discharged. Fifteen (29%) patients were still alive at 1-year outpatient department (OPD) follow-up. CONCLUSIONS: ECMO provides a good temporary cardiopulmonary support in patients with postcardiotomy shock. The preoperative risk factors of failure to withdraw ECMO are poor left-ventricular ejection fraction, systolic blood pressure <90 mmHg and refractory severe metabolic acidosis. The peri-ECMO predictors of mortality include low serum albumin level, low platelet count, low oxygen pressure of the venous tube of the ECMO and poor cardiac systolic function. Crown Copyright 2009. Published by Elsevier B.V. All rights reserved.
Authors: Joo Han Song; Won Ki Woo; Seung Hwan Song; Hyo Hyun Kim; Bong Joon Kim; Ha Eun Kim; Do Jung Kim; Jee Won Suh; Yu Rim Shin; Han Ki Park; Seung Hyun Lee; Hyun Chel Joo; Sak Lee; Byung Chul Chang; Kyung Jong Yoo; Young Sam Kim; Young Nam Youn Journal: J Thorac Dis Date: 2016-07 Impact factor: 2.895
Authors: Shinichi Fukuhara; Koji Takeda; Arthur Reshad Garan; Paul Kurlansky; Jonathan Hastie; Yoshifumi Naka; Hiroo Takayama Journal: Gen Thorac Cardiovasc Surg Date: 2016-02-13
Authors: Claudia Heilmann; Ulrich Geisen; Friedhelm Beyersdorf; Lea Nakamura; Christoph Benk; Georg Trummer; Michael Berchtold-Herz; Christian Schlensak; Barbara Zieger Journal: Intensive Care Med Date: 2011-10-01 Impact factor: 17.440
Authors: Paolo Meani; Matteo Matteucci; Federica Jiritano; Dario Fina; Francesco Panzeri; Giuseppe M Raffa; Mariusz Kowalewski; Nuccia Morici; Giovanna Viola; Alice Sacco; Fabrizio Oliva; Amal Alyousif; Sam Heuts; Martijn Gilbers; Rick Schreurs; Jos Maessen; Roberto Lorusso Journal: Ann Cardiothorac Surg Date: 2019-01
Authors: Roberto Lorusso; Giuseppe Maria Raffa; Khalid Alenizy; Niels Sluijpers; Maged Makhoul; Daniel Brodie; Mike McMullan; I-Wen Wang; Paolo Meani; Graeme MacLaren; Mariusz Kowalewski; Heidi Dalton; Ryan Barbaro; Xiaotong Hou; Nicholas Cavarocchi; Yih-Sharng Chen; Ravi Thiagarajan; Peta Alexander; Bahaaldin Alsoufi; Christian A Bermudez; Ashish S Shah; Jonathan Haft; David A D'Alessandro; Udo Boeken; Glenn J R Whitman Journal: J Heart Lung Transplant Date: 2019-08-10 Impact factor: 10.247